Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for behavioural problems and hyperphagia in children with Prader-Willi syndrome
2016-003273-18Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Intranasal oxytocin with Placebo (2 arms). Primary endpoint: Change in behavioural troubles (CBCL global score). Started Aug 2016; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2016-003273-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003273-18.